Bouhour J B, Potiron M, Chiffoleau S, Lefévre M, Louvet S
Arch Mal Coeur Vaiss. 1987 Jan;80(1):76-82.
It remains difficult to make a reasoned choice between betablockers and calcium antagonists in the medical treatment of hypertrophic cardiomyopathy. In order to help in making this choice, we compared the effects of 320 mg of propranolol and 480 mg of verapamil, prescribed in a random order for an average period of 2.5 months in 24 patients. In 15 patients the two therapeutic sequences were preceded and followed by a clinical examination and an exercise stress test after withdrawal of all treatment. The overall functional status correlated to oxygen consumption was unchanged by the two drugs, but patients felt better more often with verapamil. These was no significant change in maximal power developed during exercise testing although verapamil increased it by 9 p. 100 throughout with a corresponding increase in oxygen consumption. Two parameters were significantly changed by both drugs: the maximal heart rate fell from 161 +/- 22 to 122 +/- 18 with propranolol, and to 145 +/- 28 with verapamil; the oxygen pulse (equivalent to the systolic index) increased from 10.9 +/- 2.2 to 14.8 +/- 3.9 with propranolol, and to 13.7 +/- 2.4 with verapamil. There were no changes in the blood pressure profiles during exercise. Side effects were observed with both drugs; muscular weakness was the biggest problem with propranolol and sinus node dysfunction with verapamil.(ABSTRACT TRUNCATED AT 250 WORDS)
在肥厚型心肌病的药物治疗中,很难在β受体阻滞剂和钙拮抗剂之间做出合理选择。为了帮助做出这一选择,我们比较了320毫克普萘洛尔和480毫克维拉帕米的效果,对24例患者随机给药,平均给药期为2.5个月。在15例患者中,两种治疗顺序前后都进行了临床检查以及在停止所有治疗后进行运动应激试验。两种药物对与耗氧量相关的整体功能状态没有影响,但服用维拉帕米的患者感觉更好的情况更常见。运动测试期间的最大运动能力没有显著变化,尽管维拉帕米使其整体提高了9%,耗氧量也相应增加。两种药物都使两个参数发生了显著变化:服用普萘洛尔时,最大心率从161±22降至122±18,服用维拉帕米时降至145±28;氧脉搏(相当于收缩期指数)服用普萘洛尔时从10.9±2.2升至14.8±3.9,服用维拉帕米时升至13.7±2.4。运动期间的血压情况没有变化。两种药物都观察到了副作用;肌肉无力是普萘洛尔最大的问题,而维拉帕米则是窦房结功能障碍。(摘要截选至250字)